Brief: Mirum Pharmaceuticals Announces Enrollment Completion In The Phase 2B Vistas Study
08/09/2025 13:16
Sept 8 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O: MIRUM PHARMACEUTICALS ANNOUNCES ENROLLMENT COMPLETION IN THE PHASE 2B VISTAS STUDY MIRUM PHARMACEUTICALS INC - TOPLINE RESULTS FROM VISTAS STUDY EXPECTED IN Q2 2025 Source text: ID:nBw8M2cpva Further company coverage: MIRM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX